On the role of CEACAM5 in the growth and progression of NSCLC, including the mechanism of action, current safety and efficacy data, and results from from recent trials.
EP. 1: Overview of the NSCLC Landscape, Prognosis, and Biomarker-Driven Treatments
A comprehensive overview of the current landscape of non-small cell lung cancer (NSCLC), highlighting the impact of biomarkers on treatment selection.
EP. 2: Emerging Biomarkers and Targeted Therapies in NSCLC
The discussion centered around emergent biomarkers and targeted therapies in NSCLC, exploring targets like CEACAM5, TROP2, HER3, cMET, and the potential role of antibody drug conjugates in refractory disease.
EP. 3: CEACAM5: Role, Expression, and Therapeutic Potential in NSCLC
The role of CEACAM5, its expression in NSCLC, and its potential as a therapeutic target are thoroughly examined, including its impact on tumorigenesis and prognosis in NSCLC patients.
EP. 4: CEACAM5 Testing in Clinical Practice
Experts share their approach to CEACAM5 testing, including the testing procedure, patient selection criteria, and timing of testing.
EP. 5: Clinical Pearls: Treating Different Patient Populations in NSCLC
Dr. Florez and Dr. Sabari discuss standards of care for different patient populations in NSCLC.
EP. 6: Transforming the NSCLC Treatment Landscape with Antibody Drug Conjugates
The transformative potential of antibody drug conjugates in NSCLC treatment is discussed, encompassing their design, bystander effect, biomarkers, and impact on the treatment landscape.
EP. 7: CARMEN-LC03 and CARMEN-LC04 Trials: Study Design and Anticipated Findings
An overview of the CARMEN-LC03 and CARMEN-LC04 trials investigating tusa in different treatment settings for NSCLC and their impact on treatment approaches is provided.
EP. 8: Efficacy and Safety of Tusa with Pembrolizumab and Chemotherapy in NSCLC: CARMEN-LC05 Study
Important findings from the CARMEN-LC05 study evaluating tusa in combination with pembrolizumab and chemotherapy in NSCLC are discussed, highlighting their implications for clinical practice.
EP. 9: Recent Progress and Unmet Needs in NSCLC
Dr. Florez and Dr. Sabari delve into areas of progress, unmet needs, and future research in NSCLC, encompassing novel biomarkers and targeted therapies such as CEACAM5.
2 Clarke Drive Cranbury, NJ 08512